Library Portal | UWC Portal | National ETDs | Global ETDs
    • Login
    Contact Us | About Us | FAQs | Login
    View Item 
    •   DSpace Home
    • Faculty of Natural Sciences
    • School of Pharmacy
    • Research Articles (School of Pharmacy)
    • View Item
    •   DSpace Home
    • Faculty of Natural Sciences
    • School of Pharmacy
    • Research Articles (School of Pharmacy)
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Small molecule efflux pump inhibitors in Mycobacterium tuberculosis: a rational drug design perspective

    Thumbnail
    View/Open
    Kapp_Small-molecule_2018.pdf (924.6Kb)
    Date
    2018
    Author
    Kapp, Erika
    Malan, Sarel F.
    Joubert, Jacques
    Sampson, Samantha L.
    Metadata
    Show full item record
    Abstract
    Drug resistance in Mycobacterium tuberculosis (M. tuberculosis) complicates management of tuberculosis. Efflux pumps contribute to low level resistance and acquisition of additional high level resistance mutations through sub-therapeutic concentrations of intracellular antimycobacterials. Various efflux pump inhibitors (EPIs) have been described for M. tuberculosis but little is known regarding the mechanism of efflux inhibition. As knowledge relating to the mechanism of action and drug target is central to the rational drug design of safe and sufficiently selective EPIs, this review aims to examine recent developments in the study of EPIs in M. tuberculosis from a rational drug development perspective and to provide an overview to facilitate systematic development of therapeutically effective EPIs. Review of literature points to a reduction in cellular energy or direct binding to the efflux pump as likely mechanisms for most EPIs described for M. tuberculosis. This review demonstrates that, where a direct interaction with efflux pumps is expected, both molecular structure and general physicochemical properties should be considered to accurately predict efflux pump substrates and inhibitors. Non-competitive EPIs do not necessarily demonstrate the same requirements as competitive inhibitors and it is therefore essential to differentiate between competitive and non-competitive inhibition to accurately determine structure activity relationships for efflux pump inhibition. It is also evident that there are various similarities between inhibitors of prokaryotic and eukaryotic efflux pumps but, depending on the specific chemical scaffolds under investigation, it may be possible to design EPIs that are less prone to inhibition of human P-glycoprotein, thereby reducing side effects and drug-drug interactions.
    URI
    http://dx.doi.org/10.2174/1389557517666170510105506
    http://hdl.handle.net/10566/3397
    Collections
    • Research Articles (School of Pharmacy)

    DSpace 6.3 | Ubuntu | Copyright © University of the Western Cape
    Contact Us | Send Feedback
    Theme by 
    Atmire NV
     

     

    Browse

    All of DSpaceCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects

    My Account

    Login

    Statistics

    View Usage Statistics

    DSpace 6.3 | Ubuntu | Copyright © University of the Western Cape
    Contact Us | Send Feedback
    Theme by 
    Atmire NV